Journal of Dental Sciences (Oct 2022)

Establishment of an oral squamous cell carcinoma cell line expressing vascular endothelial growth factor a and its two receptors

  • Hanako Araki-Maeda,
  • Mutsuki Kawabe,
  • Yuji Omori,
  • Koji Yamanegi,
  • Kazunari Yoshida,
  • Kyohei Yoshikawa,
  • Kazuki Takaoka,
  • Kazuma Noguchi,
  • Yoshiro Nakano,
  • Hiromitsu Kishimoto

Journal volume & issue
Vol. 17, no. 4
pp. 1471 – 1479

Abstract

Read online

Background/purpose: Vascular endothelial growth factor receptor (VEGFR) expression in oral squamous cell carcinoma (OSCC) promotes tumor growth through both autocrine and paracrine signaling. VEGF-positive OSCC cases are associated with a high depth of invasion, increased metastasis, and poor prognosis. In this study we established and then molecularly and functionally analyzed an OSCC cell line that co-expresses VEGF-A, VEGFR-1, and VEGFR-2, termed HCM-SqCC010 cells. Materials and methods: VEGF-A, VEGFR-1, and VEGFR-2 expression in HCM-SqCC010 cells were examined by immunohistochemistry and immunoblotting. Expression and inhibition of VEGF-A, VEGFR-1, and VEGFR-2 in HCM-SqCC010 cells were verified by quantitative real-time PCR. Results: Our analysis of HCM-SqCC010 cells revealed that their proliferation depended on VEGF-A, and selective inhibition of VEGFR-1 or VEGFR-2 resulted in decreased cell growth. Conclusion: We established an OSCC cell line, HCM-SqCC010, that expresses VEGF-A, VEGFR-1, and VEGFR-2. This triple-positive cell line showed no effect from a molecular targeted drug toward VEGF-A, but it did show strong cell growth inhibition in response to a VEGFR inhibitor. Thus, new therapeutic strategies against OSCC should include a VEGFR inhibitor.

Keywords